Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor

被引:24
|
作者
Clark, Lorraine N. [1 ,2 ,3 ]
Kisselev, Sergey [2 ]
Park, Naeun [4 ]
Ross, Barbara [1 ]
Verbitsky, Miguel [1 ]
Rios, Eileen [4 ]
Alcalay, Roy N. [5 ]
Lee, Joseph H. [1 ,3 ,4 ,6 ]
Louis, Elan D. [1 ,4 ,5 ,6 ]
机构
[1] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA
[2] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA
[3] Columbia Univ, Coll Phys & Surg, Ctr Human Genet, New York, NY 10032 USA
[4] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA
[5] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA
[6] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA
基金
美国国家卫生研究院;
关键词
Essential tremor; LRRK2; GBA mutation; Association; Risk factor; DOMINANT; VARIANT; COMMON;
D O I
10.1016/j.parkreldis.2009.05.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We evaluated an association between essential tremor (ET) and the Parkinson's disease (PD) genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA). Clinical studies demonstrate an association between ET and PD, suggesting possible shared pathophysiologies, yet LRRK2 has rarely been Studied in ET, and GBA, not at all. ET cases (n = 275, including 42 with rest tremor) and controls (n = 289) were enrolled in an epidemiological study (Columbia University). Post-mortem brain tissue samples were obtained on 24 additional ET cases, including 3 with brainstem Lewy bodies. We performed a comprehensive analysis of the LRRK2 gene by genotyping 4 LRRK2 mutations (G2019S, 12020T, R1441C and Y1699C), 2 rare LRRK2 variants (L1114L and 11122V) and 19 LRRK2 SNPs. All GBA exons were sequenced in a subset of 93 Ashkenazi Jewish (AJ) cases, 62 AJ controls and 24 ET brains. LRRK2 mutations were not found in any ET cases or ET brains and none of the LRRK2 SNPs was associated with ET. GBA mutations were found in 7.5% (7/93) of AJ ET cases and 4.8% (3/62) of AJ controls (p = 0.75). 8.3% (2/24) of ET brains carried a GBA mutation. Four different heterozygous mutations were identified, including 3 previously reported mutations (N370S, R496H, and E32610 and I new missense variant (R44C). As suggested by several smaller prior reports, the known mutations for the LRRK2 gene are not risk factors for FT. Furthermore, a similar frequency of GBA mutations in AJ ET cases and controls suggests that GBA is not a common cause of ET either. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:132 / 135
页数:4
相关论文
共 50 条
  • [1] Analysis of the Parkinson's Disease Genes, LRRK2 and GBA, in Essential Tremor
    Clark, Lorraine N.
    Park, Naeun
    Kisselev, Sergey
    Ross, Barbara
    Rios, Eileen
    Lee, Joseph H.
    Louis, Elan D.
    NEUROLOGY, 2009, 72 (11) : A166 - A166
  • [2] The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    Cookson, Mark R.
    NATURE REVIEWS NEUROSCIENCE, 2010, 11 (12) : 791 - 797
  • [3] The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    Mark R. Cookson
    Nature Reviews Neuroscience, 2010, 11 : 791 - 797
  • [4] Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease
    Bardien, Soraya
    Lesage, Suzanne
    Brice, Alexis
    Carr, Jonathan
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (07) : 501 - 508
  • [5] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [6] Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond
    Bae, Jae Ryul
    Lee, Byoung Dae
    BMB REPORTS, 2015, 48 (05) : 243 - 248
  • [7] Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
    Lee, Byoung Dae
    Dawson, Valina L.
    Dawson, Ted M.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (07) : 365 - 373
  • [8] Leucine-Rich Repeat Kinase 2 (LRRK2): A Key Player in the Pathogenesis of Parkinson's Disease
    Gandhi, Payal N.
    Chen, Shu G.
    Wilson-Delfosse, Amy L.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2009, 87 (06) : 1283 - 1295
  • [9] A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
    Vissers, Maurits F. J. M.
    Troyer, Matthew D.
    Thijssen, Eva
    Heuberger, Jules A. A. C.
    Groeneveld, Geert Jan
    Huntwork-Rodriguez, Sarah
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (08): : 1408 - 1420
  • [10] Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian
    Belin, Andrea Carmine
    Westerlund, Marie
    Sydow, Olof
    Lundstromer, Karin
    Hakansson, Anna
    Nissbrandt, Hans
    Olson, Lars
    Galter, Dagmar
    MOVEMENT DISORDERS, 2006, 21 (10) : 1731 - 1734